Search Results
Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China
Search for other papers by Junyu Tong in
Google Scholar
PubMed
Department of Nuclear Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People’s Republic of China
Search for other papers by Maomei Ruan in
Google Scholar
PubMed
Search for other papers by Yuchen Jin in
Google Scholar
PubMed
Search for other papers by Hao Fu in
Google Scholar
PubMed
Search for other papers by Lin Cheng in
Google Scholar
PubMed
Search for other papers by Qiong Luo in
Google Scholar
PubMed
Department of Pathology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China
Search for other papers by Zhiyan Liu in
Google Scholar
PubMed
Search for other papers by Zhongwei Lv in
Google Scholar
PubMed
Search for other papers by Libo Chen in
Google Scholar
PubMed
Introduction The incidence of thyroid cancer, the most common endocrine malignancy, has been increasing over the past decades. More than 87% of thyroid cancers are distinguished as differentiated thyroid carcinoma (DTC), including papillary
Search for other papers by Lucie Allard in
Google Scholar
PubMed
Search for other papers by Jérôme Alexandre Denis in
Google Scholar
PubMed
Search for other papers by Gaëlle Godiris Petit in
Google Scholar
PubMed
Search for other papers by Gabrielle Deniziaut in
Google Scholar
PubMed
Search for other papers by Cécile Ghander in
Google Scholar
PubMed
Search for other papers by Elise Mathy in
Google Scholar
PubMed
Search for other papers by Erell Guillerm in
Google Scholar
PubMed
Search for other papers by Charlotte Lussey-Lepoutre in
Google Scholar
PubMed
Search for other papers by Laurence Leenhardt in
Google Scholar
PubMed
Search for other papers by Camille Buffet in
Google Scholar
PubMed
compressive symptoms. The patient had refused surgery on a 6 cm-papillary thyroid carcinoma (PTC) diagnosed 3 years earlier. Initially, considering the size of the tumor, anaplastic or at least poorly differentiated carcinoma was suspected. Unexpectedly, but
Search for other papers by Chantal A Lebbink in
Google Scholar
PubMed
Search for other papers by Thera P Links in
Google Scholar
PubMed
Search for other papers by Agnieszka Czarniecka in
Google Scholar
PubMed
Search for other papers by Renuka P Dias in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Search for other papers by Louise Izatt in
Google Scholar
PubMed
Search for other papers by Heiko Krude in
Google Scholar
PubMed
Search for other papers by Kerstin Lorenz in
Google Scholar
PubMed
Search for other papers by Markus Luster in
Google Scholar
PubMed
Search for other papers by Kate Newbold in
Google Scholar
PubMed
Search for other papers by Arnoldo Piccardo in
Google Scholar
PubMed
Search for other papers by Manuel Sobrinho-Simões in
Google Scholar
PubMed
Search for other papers by Toru Takano in
Google Scholar
PubMed
Search for other papers by A S Paul van Trotsenburg in
Google Scholar
PubMed
Search for other papers by Frederik A Verburg in
Google Scholar
PubMed
Search for other papers by Hanneke M van Santen in
Google Scholar
PubMed
Introduction Pediatric differentiated thyroid carcinoma (DTC) is a rare disease; however, its worldwide incidence is rising ( 1 , 2 ). DTC comprises several histological subtypes, with papillary thyroid carcinoma (PTC) accounting for the vast
Search for other papers by João Roque in
Google Scholar
PubMed
NOVA Medical School | Faculdade de Ciências Médicas of Universidade NOVA de Lisboa, Lisbon, Portugal
Unidade Investigação Patobiologia Molecular, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Search for other papers by Tiago Nunes Silva in
Google Scholar
PubMed
Search for other papers by Catarina Regala in
Google Scholar
PubMed
Search for other papers by Ricardo Rodrigues in
Google Scholar
PubMed
NOVA Medical School | Faculdade de Ciências Médicas of Universidade NOVA de Lisboa, Lisbon, Portugal
Unidade Investigação Patobiologia Molecular, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Search for other papers by Valeriano Leite in
Google Scholar
PubMed
Introduction The term poorly differentiated thyroid carcinoma (PDTC) was first introduced by Granner and colleagues in 1963, although it was only recognized as a distinct entity by the World Health Organization in 2004 ( 1 , 2 ). In 2006, the
Search for other papers by Marie Alix Balay in
Google Scholar
PubMed
Search for other papers by Patrick Aidan in
Google Scholar
PubMed
Search for other papers by Marie Helene Schlageter in
Google Scholar
PubMed
Search for other papers by Odette Georges in
Google Scholar
PubMed
Search for other papers by Taly Meas in
Google Scholar
PubMed
Search for other papers by Maroun Bechara in
Google Scholar
PubMed
Search for other papers by Marie Elisabeth Toubert in
Google Scholar
PubMed
Search for other papers by Isabelle Faugeron in
Google Scholar
PubMed
Search for other papers by Herve Monpeyssen in
Google Scholar
PubMed
Search for other papers by Cécile N. Chougnet in
Google Scholar
PubMed
thyroidectomy surgery (TARS) was developed by Korean surgeons in 2007 [ 3 ]. Since then, this technique has been used for both benign and malignant thyroid disease. The size limit is commonly set at > 20–40 mm for low risk-differentiated thyroid carcinoma, and
Search for other papers by Fabio Maino in
Google Scholar
PubMed
Search for other papers by Cristina Dalmiglio in
Google Scholar
PubMed
Search for other papers by Nicoletta Benenati in
Google Scholar
PubMed
Search for other papers by Michele Campanile in
Google Scholar
PubMed
Search for other papers by Tania Pilli in
Google Scholar
PubMed
Search for other papers by Raffaella Forleo in
Google Scholar
PubMed
Search for other papers by Lucia Brilli in
Google Scholar
PubMed
Search for other papers by Cristina Ciuoli in
Google Scholar
PubMed
Search for other papers by Silvia Cantara in
Google Scholar
PubMed
Search for other papers by Marco Capezzone in
Google Scholar
PubMed
Search for other papers by Alessandra Cartocci in
Google Scholar
PubMed
Search for other papers by Furio Pacini in
Google Scholar
PubMed
Search for other papers by Maria Grazia Castagna in
Google Scholar
PubMed
those without (3.9 vs. 3.0%). Differentiated thyroid carcinoma (DTC) has been reported to be associated with CCH and high levels of basal CT [ 18 ]. It has been proposed that these tumors may release substances that have a paracrine stimulatory action
Search for other papers by L.A. Jonker in
Google Scholar
PubMed
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Search for other papers by C.A. Lebbink in
Google Scholar
PubMed
Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands
Search for other papers by M.C.J. Jongmans in
Google Scholar
PubMed
Department of Pediatric Radiology and Nuclear Medicine, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands
Search for other papers by R.A.J. Nievelstein in
Google Scholar
PubMed
Search for other papers by J.H.M. Merks in
Google Scholar
PubMed
Search for other papers by E.J.M. Nieveen van Dijkum in
Google Scholar
PubMed
Search for other papers by T.P. Links in
Google Scholar
PubMed
Search for other papers by N. Hoogerbrugge in
Google Scholar
PubMed
Search for other papers by A.S.P. van Trotsenburg in
Google Scholar
PubMed
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Search for other papers by H.M. van Santen in
Google Scholar
PubMed
neoplasms, including carcinomas of the breast, thyroid gland, endometrium, colon, and kidney [ 2 ]. Differentiated thyroid carcinoma (DTC) is one of the common cancer types in patients with PHTS, with a lifetime risk of 35–38% [ 2 ]. This increased risk is
Unit of Endocrinology, Department of Medical Specialties, Azienda Ospedaliero-Universitaria, Modena, Italy
Search for other papers by Giulia Brigante in
Google Scholar
PubMed
Search for other papers by Clara Lazzaretti in
Google Scholar
PubMed
Search for other papers by Elia Paradiso in
Google Scholar
PubMed
Search for other papers by Federico Nuzzo in
Google Scholar
PubMed
Search for other papers by Martina Sitti in
Google Scholar
PubMed
Search for other papers by Frank Tüttelmann in
Google Scholar
PubMed
Search for other papers by Gabriele Moretti in
Google Scholar
PubMed
Search for other papers by Roberto Silvestri in
Google Scholar
PubMed
Search for other papers by Federica Gemignani in
Google Scholar
PubMed
Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany
Search for other papers by Asta Försti in
Google Scholar
PubMed
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
Search for other papers by Kari Hemminki in
Google Scholar
PubMed
Search for other papers by Rossella Elisei in
Google Scholar
PubMed
Search for other papers by Cristina Romei in
Google Scholar
PubMed
Search for other papers by Eric Adriano Zizzi in
Google Scholar
PubMed
Search for other papers by Marco Agostino Deriu in
Google Scholar
PubMed
Unit of Endocrinology, Department of Medical Specialties, Azienda Ospedaliero-Universitaria, Modena, Italy
Center for Genomic Research, University of Modena and Reggio Emilia, Modena, Italy
Search for other papers by Manuela Simoni in
Google Scholar
PubMed
Search for other papers by Stefano Landi in
Google Scholar
PubMed
Center for Genomic Research, University of Modena and Reggio Emilia, Modena, Italy
Search for other papers by Livio Casarini in
Google Scholar
PubMed
Introduction Thyroid cancer is the most common endocrine neoplasia with a worldwide estimated age-standardized incidence rate of 6.7 per 100,000 in 2018 ( 1 ). Differentiated thyroid carcinoma (DTC) is the most frequent subtype of thyroid
Search for other papers by Xian Qiu in
Google Scholar
PubMed
Search for other papers by Lin Cheng in
Google Scholar
PubMed
Department of Nuclear Medicine, The First Hospital of Jilin University, Changchun, China
Search for other papers by Ri Sa in
Google Scholar
PubMed
Department of Nuclear Medicine & Minnan PET Center, The First Affiliated Hospital of Xiamen University, Xiamen, China
Search for other papers by Hao Fu in
Google Scholar
PubMed
Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Search for other papers by Yuchen Jin in
Google Scholar
PubMed
Search for other papers by Libo Chen in
Google Scholar
PubMed
treatment group, n = 14), and patients with RR-DTC who had failed to first-line sorafenib treatment (salvage treatment group, n = 14). Table 1 Baseline characteristics of differentiated thyroid carcinoma patients treated with apatinib
Search for other papers by Bernadette L Dekker in
Google Scholar
PubMed
Department of Emergency Medicine, Maastricht University Medical Center, Maastricht, the Netherlands
Search for other papers by Anouk N A van der Horst-Schrivers in
Google Scholar
PubMed
Search for other papers by Adrienne H Brouwers in
Google Scholar
PubMed
Search for other papers by Christopher M Shuford in
Google Scholar
PubMed
Search for other papers by Ido P Kema in
Google Scholar
PubMed
Search for other papers by Anneke C Muller Kobold in
Google Scholar
PubMed
Search for other papers by Thera P Links in
Google Scholar
PubMed
Introduction In the follow-up of patients with differentiated thyroid carcinoma (DTC), thyroglobulin (Tg) is a well-recognized tumor marker, and therefore, highly accurate Tg measurements are crucial ( 1 ). However, current immunoassays can